Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun 11:12:659064.
doi: 10.3389/fneur.2021.659064. eCollection 2021.

Paroxysmal Movement Disorders

Affiliations
Review

Paroxysmal Movement Disorders

Susan Harvey et al. Front Neurol. .

Abstract

Paroxysmal movement disorders (PxMDs) are a clinical and genetically heterogeneous group of movement disorders characterized by episodic involuntary movements (dystonia, dyskinesia, chorea and/or ataxia). Historically, PxMDs were classified clinically (triggers and characteristics of the movements) and this directed single-gene testing. With the advent of next-generation sequencing (NGS), how we classify and investigate PxMDs has been transformed. Next-generation sequencing has enabled new gene discovery (RHOBTB2, TBC1D24), expansion of phenotypes in known PxMDs genes and a better understanding of disease mechanisms. However, PxMDs exhibit phenotypic pleiotropy and genetic heterogeneity, making it challenging to predict genotype based on the clinical phenotype. For example, paroxysmal kinesigenic dyskinesia is most commonly associated with variants in PRRT2 but also variants identified in PNKD, SCN8A, and SCL2A1. There are no radiological or biochemical biomarkers to differentiate genetic causes. Even with NGS, diagnosis rates are variable, ranging from 11 to 51% depending on the cohort studied and technology employed. Thus, a large proportion of patients remain undiagnosed compared to other neurological disorders such as epilepsy, highlighting the need for further genomic research in PxMDs. Whole-genome sequencing, deep-sequencing, copy number variant analysis, detection of deep-intronic variants, mosaicism and repeat expansions, will improve diagnostic rates. Identifying the underlying genetic cause has a significant impact on patient care, modification of treatment, long-term prognostication and genetic counseling. This paper provides an update on the genetics of PxMDs, description of PxMDs classified according to causative gene rather than clinical phenotype, highlighting key clinical features and providing an algorithm for genetic testing of PxMDs.

Keywords: episodic ataxia; genetics; next-generation sequencing; paroxysmal dyskinesia; paroxysmal movement disorders.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Approach to the genetic investigation of paroxysmal movement disorders. Will not be required if using whole-genome sequencing. *The number of genes varies depending on the NGS panel used. Always check what genes are included in the panel.

Similar articles

Cited by

References

    1. Demirkiran M, Jankovic J. Paroxysmal dyskinesias: clinical features and classification. Ann Neurol. (1995) 38:571–9. 10.1002/ana.410380405 - DOI - PubMed
    1. Silveira-Moriyama L, Kovac S, Kurian MA, Houlden H, Lees AJ, Walker MC, et al. . Phenotypes, genotypes, and the management of paroxysmal movement disorders. Dev Med Child Neurol. (2018) 60:559–65. 10.1111/dmcn.13744 - DOI - PubMed
    1. Delorme C, Giron C, Bendetowicz D, Méneret A, Mariani LL, Roze E. Current challenges in the pathophysiology, diagnosis and treatment of paroxysmal movement disorders. Expert Rev Neurother. (2020) 21:81–97. 10.1080/14737175.2021.1840978 - DOI - PubMed
    1. Gardiner AR, Jaffer F, Dale RC, Labrum R, Erro R, Meyer E, et al. . The clinical and genetic heterogeneity of paroxysmal dyskinesias. Brain. (2015) 138 (Pt 12):3567–80. 10.1093/brain/awv310 - DOI - PMC - PubMed
    1. Straub J, Konrad EDH, Grüner J, Toutain A, Bok LA, Cho MT, et al. . Missense variants in RHOBTB2 cause a developmental and epileptic encephalopathy in humans, and altered levels cause neurological defects in drosophila. Am J Hum Genet. (2018) 102:44–57. 10.1016/j.ajhg.2017.11.008 - DOI - PMC - PubMed

LinkOut - more resources